Literature DB >> 9590396

Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry.

A J Pesce1, M Rashkin, U Kotagal.   

Abstract

Theophylline is used in the treatment of asthma and chronic obstructive pulmonary disease. The use of theophylline has declined with the advent of potent steroid inhalants. Because of the therapeutic index of this drug, monitoring of theophylline concentrations in plasma is essential. Monitoring should be done on trough specimens after steady-state has been reached. Non-steady-state concentrations may be indicated in selected situations. Caffeine is used to treat apnea of the newborn because of its low toxicity. Monitoring is often by clinical effect. Monitoring of serum concentrations should be performed in cases where there is no clinical response or if there is suspected toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590396

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Reply to: 'Is the use of prophylactic theophylline safe for the prevention of severe renal dysfunction in term and post-term neonates with perinatal asphyxia?'.

Authors:  H Al-Wassia
Journal:  J Perinatol       Date:  2014-01       Impact factor: 2.521

Review 2.  Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.

Authors:  Katherine Schoen; Tian Yu; Chris Stockmann; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

3.  Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates.

Authors:  Tian Yu; Alfred H Balch; Robert M Ward; E Kent Korgenski; Catherine M T Sherwin
Journal:  BMC Pharmacol Toxicol       Date:  2016-06-07       Impact factor: 2.483

Review 4.  Caffeine in preterm infants: where are we in 2020?

Authors:  Laura Moschino; Sanja Zivanovic; Caroline Hartley; Daniele Trevisanuto; Eugenio Baraldi; Charles Christoph Roehr
Journal:  ERJ Open Res       Date:  2020-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.